Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 30, 2009Eisai Plans to Submit Marketing Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer
Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced...
-
Oct 28, 2009
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody...
-
Sep 24, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in...
-
Sep 23, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases...
-
Jul 15, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology...